PriceTargets.com logo

Definitive Healthcare - DH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.72
  • Forecasted Upside: 36.90%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.18 As of 12/20/2024 06:16 PM ET
▲ +0.04 (0.97%)

This chart shows the closing price for DH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Definitive Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DH

Analyst Price Target is $5.72
▲ +36.90% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Definitive Healthcare in the last 3 months. The average price target is $5.72, with a high forecast of $8.00 and a low forecast of $4.00. The average price target represents a 36.90% upside from the last price of $4.18.

This chart shows the closing price for DH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 12 contributing investment analysts is to hold stock in Definitive Healthcare. This rating has held steady since December 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024StephensInitiated CoverageEqual Weight$5.00
11/8/2024Needham & Company LLCReiterated RatingHold
9/17/2024BTIG ResearchInitiated CoverageBuy$7.00
8/9/2024Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$7.00 ➝ $5.00
8/7/2024Robert W. BairdLower TargetNeutral ➝ Neutral$6.00 ➝ $5.00
8/7/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$6.00 ➝ $4.00
8/6/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$9.00 ➝ $5.00
8/6/2024Needham & Company LLCReiterated RatingHold
7/31/2024Stifel NicolausLower TargetBuy ➝ Buy$9.50 ➝ $7.50
7/31/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $6.00
7/31/2024Needham & Company LLCReiterated RatingHold
7/31/2024Robert W. BairdLower TargetNeutral ➝ Neutral$8.00 ➝ $6.00
7/31/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$7.00 ➝ $5.00
5/14/2024William BlairReiterated RatingOutperform
5/9/2024Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$10.00 ➝ $7.00
5/9/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$11.00 ➝ $7.00
5/8/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$10.00 ➝ $8.00
5/8/2024Stifel NicolausLower TargetBuy ➝ Buy$11.00 ➝ $9.50
5/8/2024Needham & Company LLCReiterated RatingHold
5/8/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$11.50 ➝ $9.00
3/1/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$10.00 ➝ $11.00
2/29/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$9.00 ➝ $10.00
1/17/2024Stifel NicolausLower TargetBuy ➝ Buy$12.00 ➝ $11.00
1/17/2024Needham & Company LLCDowngradeBuy ➝ Hold
1/5/2024Canaccord Genuity GroupDowngradeBuy ➝ Hold
1/5/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$10.00
11/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$15.50 ➝ $9.50
8/16/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$17.00 ➝ $10.50
8/15/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$13.00 ➝ $12.00
8/15/2023Morgan StanleyLower TargetOverweight ➝ Overweight$17.00 ➝ $15.50
8/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
8/15/2023Bank of AmericaLower TargetNeutral ➝ Neutral$12.00 ➝ $10.50
8/1/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
7/24/2023Robert W. BairdDowngradeOutperform ➝ Neutral$13.00
5/8/2023BarclaysLower Target$11.00 ➝ $10.00
5/5/2023Robert W. BairdLower Target$15.00 ➝ $13.00
4/19/2023William BlairInitiated CoverageOutperform
2/28/2023Morgan StanleyLower TargetOverweight$18.00 ➝ $17.00
2/24/2023Needham & Company LLCReiterated RatingBuy$15.00
2/24/2023Credit Suisse GroupLower TargetNeutral$19.00 ➝ $15.00
1/6/2023Morgan StanleyLower TargetOverweight$21.00 ➝ $18.00
12/14/2022Robert W. BairdBoost Target$15.00
12/9/2022Bank of AmericaInitiated CoverageNeutral$13.00
11/7/2022The Goldman Sachs GroupLower TargetNeutral$31.00 ➝ $17.00
11/4/2022Morgan StanleyLower TargetOverweight$23.00 ➝ $21.00
11/4/2022Needham & Company LLCLower TargetBuy$32.00 ➝ $15.00
11/4/2022Credit Suisse GroupLower TargetNeutral$24.00 ➝ $19.00
10/24/2022Morgan StanleyLower TargetOverweight$34.00 ➝ $23.00
10/11/2022BarclaysLower Target$23.00 ➝ $18.00
8/8/2022BarclaysLower TargetEqual Weight$24.00 ➝ $23.00
8/8/2022Morgan StanleyLower TargetOverweight$37.00 ➝ $34.00
7/6/2022Needham & Company LLCInitiated CoverageBuy$30.00
4/5/2022Deutsche Bank AktiengesellschaftBoost TargetHold$21.00 ➝ $26.00
2/24/2022Canaccord Genuity GroupUpgradeHold ➝ Buy
2/24/2022BarclaysLower Target$26.00 ➝ $23.00
2/24/2022Credit Suisse GroupLower TargetNeutral$30.00 ➝ $24.00
1/25/2022Deutsche Bank AktiengesellschaftLower TargetHold$45.00 ➝ $21.00
1/19/2022BarclaysLower TargetEqual Weight$47.00 ➝ $26.00
12/16/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$46.00 ➝ $40.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$36.00
11/16/2021Robert W. BairdInitiated CoverageOutperform$50.00
11/10/2021Deutsche Bank AktiengesellschaftLower TargetHold$47.00 ➝ $45.00
10/11/2021JPMorgan Chase & Co.Initiated CoverageNeutral$47.00
10/11/2021Stifel NicolausInitiated CoverageBuy$53.00
10/11/2021Raymond JamesInitiated CoverageMarket Perform
10/11/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$47.00
10/11/2021Credit Suisse GroupInitiated CoverageNeutral$50.00
10/11/2021Morgan StanleyInitiated CoverageEqual Weight$46.00
10/11/2021BarclaysInitiated CoverageEqual Weight$47.00
10/11/2021The Goldman Sachs GroupInitiated CoverageNeutral$34.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.38 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 22 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 9 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 9 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Definitive Healthcare logo
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
Read More

Today's Range

Now: $4.18
Low: $4.07
High: $4.32

50 Day Range

MA: $4.41
Low: $4.08
High: $4.77

52 Week Range

Now: $4.18
Low: $3.19
High: $10.62

Volume

852,709 shs

Average Volume

720,932 shs

Market Capitalization

$482.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Definitive Healthcare?

The following Wall Street analysts have issued research reports on Definitive Healthcare in the last year: Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Robert W. Baird, Stephens, Stifel Nicolaus, and William Blair.
View the latest analyst ratings for DH.

What is the current price target for Definitive Healthcare?

0 Wall Street analysts have set twelve-month price targets for Definitive Healthcare in the last year. Their average twelve-month price target is $5.72, suggesting a possible upside of 36.9%. Canaccord Genuity Group Inc. has the highest price target set, predicting DH will reach $8.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $4.00 for Definitive Healthcare in the next year.
View the latest price targets for DH.

What is the current consensus analyst rating for Definitive Healthcare?

Definitive Healthcare currently has 1 sell rating, 8 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DH, but not buy more shares or sell existing shares.
View the latest ratings for DH.

What other companies compete with Definitive Healthcare?

Other companies that are similar to Definitive Healthcare include Sprout Social, Marqeta, Semrush, Jamf and N-able. Learn More about companies similar to Definitive Healthcare.

How do I contact Definitive Healthcare's investor relations team?

Definitive Healthcare's physical mailing address is 550 COCHITUATE ROAD, FRAMINGHAM MA, 01701. The company's listed phone number is 508-720-4224 and its investor relations email address is [email protected]. The official website for Definitive Healthcare is www.definitivehc.com. Learn More about contacing Definitive Healthcare investor relations.